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In Brief
Siuda et al. develop a photosensitive mu-
opioid-like receptor (opto-MOR) that
triggers cAMP inhibition and MAP kinase
activation, couples to GIRK currents, and
internalizes like the mu-opioid receptor.
Photostimulation of opto-MOR within
discrete GABAergic nuclei induces real-
time preference or aversion.
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Optogenetics is now a widely accepted tool for
spatiotemporal manipulation of neuronal activity.
However, a majority of optogenetic approaches
use binary on/off control schemes. Here, we extend
the optogenetic toolset by developing a neuromodu-
latory approach using a rationale-based design to
generate a Gi-coupled, optically sensitive, mu-
opioid-like receptor, which we term opto-MOR. We
demonstrate that opto-MOR engages canonical
mu-opioid signaling through inhibition of adenylyl
cyclase, activation of MAPK and G protein-gated
inward rectifying potassium (GIRK) channels and
internalizes with kinetics similar to that of the mu-
opioid receptor. To assess in vivo utility, we ex-
pressed a Cre-dependent viral opto-MOR in RMTg/
VTA GABAergic neurons, which led to a real-time
place preference. In contrast, expression of opto-
MOR in GABAergic neurons of the ventral pallidum
hedonic cold spot led to real-time place aversion.
This tool has generalizable application for spatiotem-
poral control of opioid signaling and, furthermore,
can be used broadly for mimicking endogenous
neuronal inhibition pathways.
INTRODUCTION
Opioid receptor-targeting drugs have been used as analgesics
and recreationally abused for hundreds of years. Due to a lack
of effective alternatives, they remain on the front lines for acute
pain management, severe anti-tussive treatment, and other indi-
cations despite their high abuse potential. Mu (MOPR), kappa
(KOPR), delta (DOPR), and nociceptin opioid peptide receptors
(NOPR) persist at the forefront of basic science and drug discov-
ery efforts on disorders ranging from gastrointestinal ailments to
pain, addiction, and depression (Al-Hasani and Bruchas, 2011).Among these receptor systems, the mu-opioid receptor has
been the most intensely studied due to its long-established
involvement in analgesia, euphoria, and reward in response to
morphine-like analogs. However, despite years of study, opioid
research had been limited by a fundamental challenge. Studying
the specific effects of opioids with spatial, temporal, and cell-
type-specific control is virtually untenable, especially in the
context of the CNS. Systemic drugs bind MOPRs on heteroge-
neous cell populations across multiple brain regions. MOPR
expression at both pre- and post-synaptic sites within overlap-
ping discrete regions precludes determination of circuit level
contributions. Therefore, approaches to selectively limit engage-
ment of MOPR signaling to restricted cell populations with tem-
poral control that closely mimics endogenous opioid kinetics is a
first key step toward unraveling these issues and developing
future therapeutic strategies where opioids are the most effec-
tive treatment regimen.
Recent developments in optogenetics and molecular biology
provide an ideal strategy for addressing these questions. Class
A G protein-coupled receptors (GPCRs), including the rat
rhodopsin receptor and MOPR, have structural and functional
similarities that can be exploited to create hybrid receptors
with unique functional properties. More specifically, the light-
sensitive external portion of rhodopsin receptors can be com-
bined with internal signal transduction components of other
GPCRs to produce so-called opto-XR chimeras capable of initi-
ating and terminating receptor-specific signaling events with
temporal precision enabled by pulses of light (Airan et al.,
2009; Gunaydin et al., 2014; Kim et al., 2005; Masseck et al.,
2014). Furthermore, packaging these receptors into Cre recom-
binase-dependent viruses using loxP flanked doubled inverted
open (DIO or FLEX) reading frames allows for restricted expres-
sion in discrete cell types within isolated brain regions yielding
spatial control of GPCR signaling in vivo (Atasoy et al., 2008;
Zhang et al., 2010).
Here, we present the generation and characterization of a new
photosensitive mu-opioid-like chimeric receptor (we term opto-
MOR). We show that opto-MOR suppresses cyclic AMP (cAMP)
levels, activates MAPK signaling, and internalizes in a similar
time course to nativeMOPR. Furthermore, it functionally couplesNeuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc. 923
to GIRK channels in GABAergic neurons of the periaqueductal
gray (PAG) and rostromedial tegmental region (RMTg),
mimicking properties of native MOPR (Blanchet and Lu¨scher,
2002; Ingram et al., 2008; Matsui et al., 2014; Vaughan et al.,
2003). Finally, we demonstrate here that opto-MOR promotes
classical MOPR-mediated reward and aversion behaviors in
distinct brain circuits. Together, these findings establish opto-
MOR as a spatiotemporally precise MOPR analog and support
its utility for studying opioid circuitry and behavior.
RESULTS
Developing a Chimeric Photosensitive Receptor with
Components of the Mu-Opioid Receptor
In order to effectively generate an optically sensitive MOPR-
based receptor chimera that would have high probability of
structural similarity to mu-opioid receptors and retain native
opioid Gi/o-protein signaling, we used the closest class
A-related receptor as a backbone. Rat rhodopsin RO4 has
been previously shown to couple to Gi/o signaling pathways
in vitro and thus served as the ideal template for generation of
an opto-MOR (Hille, 1994). Using the constraint-based multiple
alignment tool (COBALT, NCBI; http://www.st-va.ncbi.nlm.nih.
gov/tools/cobalt/re_cobalt.cgi), rat rhodopsin RO4 was aligned
against rat MOPR to identify and align transmembrane, intracel-
lular, and extracellular domains (Figures 1A and S1A). To confer
MOPR-like coupling, we isolated the rhodopsin RO4 sequence,
retained the critical photoisomerizing RO4 retinal binding site
(Figures S1A and S1B), and inserted the rat MOPR intracellular
loops and C terminus (Figures S1A and S1C). A protein folding
prediction was modeled by bioinformatics software (Roy et al.,
2010) in order to accurately project how our various chimeras
would result in a seven transmembrane protein with matched
features (Figures 1A andS1D). This approach allowed for optimal
conservation of Gi/o receptor dynamics, a high degree of photo-
sensitivity, while simultaneously providing the critical intracel-
lular communication components for engaging mu-opioid
signaling pathways in vitro and in vivo.
Opto-MOR Is Photosensitive and Effectively Mimics
Mu-Opioid Signaling Dynamics
In order to determine if opto-MOR is functional and traffics to the
membrane, we first examined whether a YFP-tagged opto-MOR
expresses at the cell membrane in a pattern similar to that of the
wild-type MOPR-GFP-tagged receptor. We found that both re-
ceptors express at the plasma membrane in a similar manner
(Figures 1B and 1C) in unstimulated cells. Opioid receptor char-
acterization has demonstrated that agonist stimulation of opioid
receptors causes interactions with inhibitory G proteins (Gai) to
induce inhibition of cAMP production (Childers and Snyder,
1978; Al-Hasani and Bruchas, 2011) (Figure 1A). In order to
determine whether cells expressing opto-MOR couple to the
same canonical MOPR signaling pathways, we assessed their
response to blue LED (465 nm, 1 mW, 20 s) stimulation in a
battery of well-known in vitro opioid signaling assays in direct
parallel with wild-type rat MOPR using the high affinity, selec-
tive MOPR agonist, [D-Ala2, NMe-Phe4, Gly-ol5]-enkephalin
(DAMGO; 1 mM). First, we show that opto-MOR maintains mem-924 Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc.brane expression levels similar to that of MOPR in unstimulated
HEK293 cells (Figures 1B and 1C). Second, we found that photo-
stimulation of opto-MOR and DAMGO activation of MOPR
caused a time-locked decrease in forskolin-induced intracellular
cAMP levels with similar time constants of activation (Figures
1D–1F, S2A, S2B, S2D, and S2E). To verify the specificity of
our constructs, we show that opto-MOR does not respond to
the selective MOPR full agonist DAMGO, and likewise wild-
type MOPR does not respond to photostimulation (Figures
S2C and S2F). Additionally, we show that opto-MOR is maxi-
mally activatedwith 465 nm light and shows less efficacy at other
wavelengths in cAMP inhibition (525, 630, and 660 nm) (Fig-
ure 1G). Finally, we found that opto-MOR is highly sensitive to
light and requires very little light power for photoactivation (Fig-
ures 1H and S2G), while varying LED pulse lengths resulted in
similar levels of cAMP inhibition (Figure 1I). Opto-MOR and
MOPR caused similar levels of cyclic AMP inhibition via photosti-
mulation and agonist treatment, respectively, suggesting that
opto-MOR couples to canonical mu-opioid signaling pathways,
yet utilizes rapid time-locked photoswitching to engage Gai-
mediated inhibition of adenylyl cyclase signaling.
Agonist stimulation of all four opioid receptors has been shown
to recruit various factors resulting in mitogen-activated protein
kinase (MAPK) activation (Bruchas et al., 2011; Al-Hasani and
Bruchas, 2011). MOPR has been shown to elicit a rapid initial
peak in the phosphorylation of extracellular signaling-regulated
kinase (pERK) in neurons, astrocytes, and transfected cell cul-
tures (Belcheva et al., 2005). Here, we examined whether opto-
MOR and MOPR produce similar kinetics and efficacy in
engaging pERK signaling in HEK293 cells. In complementary ex-
periments, we found a rapid and transient increase in pERK
(2–5 min) in response to blue LED photostimulation of opto-
MORandDAMGOapplication toMOPR-expressingcells (Figures
1J–1L). pERK returned to basal levels 60–90 min after either pho-
tostimulation or DAMGO treatment. Furthermore, opto-MOR-
mediated activation of ERK was mostly independent of LED
pulse time (Figure S2H) and only mildly affected by light power
(Figure S2I), suggesting that time-locked photoactivation of
opto-MOR immediately engages the MAPK signaling cascade.
Opioid receptors are well known to be rapidly regulated by
arrestin-clathrin-mediated internalization pathways. To assess
whether opto-MOR exhibits similar activation-induced receptor
regulation and engages canonical mu-opioid receptor internali-
zation machinery, we performed side-by-side experiments
whereby we compared the kinetics and efficacy of LED or
agonist-stimulated receptor internalization on opto-MOR or
MOPR. Following photostimulation or DAMGO treatment,
respectively, both opto-MOR and MOPR internalized rapidly
(within 15 min) with similar rates of internalization (tin), with a
peak effect at 30 min after agonist or light stimulation (Figures
2A, 2B, S3A, and S3B). Opto-MOR receptors remained punctate
in the cytosol at all post-stimulation times tested, lasting up to an
hour. Opto-MOR internalization over this time course is consis-
tent with previously reported wild-type MOPR internalization by
both widely used synthetic and endogenous ligands (Al-Hasani
and Bruchas, 2011).
Agonists such as etorphine and DAMGO and endogenous
opiate peptides such as Met-enkephalin and b-endorphin have
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Figure 1. Opto-MOR and MOR Share Ca-
nonical Intracellular G Protein Signaling
Mechanisms
(A) Schematic of opto-MOR showing activation of
cAMP and pERK pathways.
(B) Opto-MOR and MOPR are highly expressed at
the membrane in HEK293 cells (scale bar, 10 mm).
(C) Opto-MOR (purple, n = 43 cells) and MOPR
(n = 37 cells) share similar surface expression in
HEK293 cells.
(D) Optical stimulation (blue bar; 20 s, 1 mW)
of opto-MOR reduces forskolin-induced (dashed
line) cAMP in HEK cells (n = 9–10 experiments).
(E) Application of DAMGO (gray bar; 1 mM) reduces
forskolin-induced (dashed line) cAMP in HEK293
cells expressing MOPR (n = 3 experiments).
(F) Light and DAMGO significantly reduce for-
skolin-induced cAMP in opto-MOR (purple; n = 12)
and MOPR (gray; n = 3).
(G) cAMP inhibition by opto-MOR is most efficient
at 465 nm (n = 6–8 experiments; *p < 0.05, **p <
0.01, ***p < 0.001 via one-way ANOVA with Bon-
ferroni’s multiple comparison test).
(H) cAMP inhibition by opto-MOR is power
dependent (n = 3–9 experiments).
(I) cAMP inhibition by opto-MOR is not dependent
on light pulse length (n = 2–10 experiments).
(J) Representative immunoblots show similar ki-
netic increases in pERK in response to light (1 min,
1mW) or DAMGO (1 mM) in opto-MOR (purple) and
MOPR (gray)-expressing cells.
(K and L) Quantification of light-induced pERK in
opto-MOR (n = 6) (K) and DAMGO-induced pERK
in MOPR (n = 2) (L). Data are represented as
mean ± SEM. See also Figures S1 and S2.been shown to cause MOPR internalization 30 min after drug
exposure, as receptor endocytosis and recycling to the mem-
brane reaches steady state around 30 and 60 min, respectively.
To test whether opto-MOR displays functional desensitization inNeuron 86, 923–addition to internalization, we photosti-
mulated opto-MOR and induced inhibi-
tion of cAMP (Figures 2C and 2F). In
parallel, we photostimulated opto-MOR
expressing HEK293 cells at saturating
power (1 mW, 20 s), waited varying de-
grees of time, and then photostimulated
again (i.e., pre-pulsed). We found that at
approximately 15 min following pre-pulse
stimulation, there is a significant loss of
opto-MOR function, with no difference
observed from the unstimulated control
cells (Figures 2D and 2F). However,
longer time periods between the two light
pulses show that within approximately
60 min there is restoration of opto-MOR
function in inhibition of cAMP (Figures
2E and 2F). However, it is unclear whether
this restoration is due to receptor recy-
cling or de novo receptor synthesis. To
address this, we repeated this experi-ment but pretreated cells with either brefeldin A, which blocks
translocation of proteins from the ER to the Golgi and has
been used in studies of MOPR recycling, or Dyngo-4a, an inhib-
itor of dynamin that prohibits receptor internalization and has935, May 20, 2015 ª2015 Elsevier Inc. 925
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B
A Figure 2. Opto-MOR and MOPR Internalization and Recovery from
Desensitization
(A) Representative images show internalization of opto-MOR (colorized yellow;
scale bar, 50 mm) and MOPR (inset, gray; scale bar, 10 mm) expressed in
HEK293 cells in response to light and DAMGO. 0, 5, 15, 30, and 45 min time
points are represented. Arrowheads show examples of internalized receptor.
(B) Quantification of receptor internalization in opto-MOR (purple; tin = 8.9 min;
n = 16–43 cells per time point over 2 experimental replicates) andMOPR (gray;
tin = 8.5 min; n = 24-38 cells per time point over 3 experimental replicates) in
response to light and DAMGO-induced activation, respectively.
(C) Opto-MOR inhibits forskolin-induced (dashed line) cAMP following light
stimulation (n = 4 traces).
(D) A second light pulse 15 min following the first shows a loss of opto-MOR
activity (n = 3–4 traces).
(E) cAMP inhibitory activity returns to baseline levels 60 min following an initial
light pulse (n = 3 traces).
(F) Time course of recovery from desensitization (n = 3–11 replicates; ***p <
0.001 via one way ANOVA followed by Dunnett’s multiple comparison test to
control). Data are represented as mean ± SEM. See also Figure S2.
926 Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc.recently been shown to prevent intracellular GPCR cAMP
signaling. Following a 1 hr interpulse interval (Figure S3D), we
found that pretreatment with brefeldin A did not prevent opto-
MOR-induced inhibition of cAMP (Figures S3C and S3E).
Furthermore, Dyngo-4a pretreated cells also show cAMP inhibi-
tion, suggesting that opto-MOR continues to inhibit cAMP from
the plasma membrane with no loss of signal when inhibiting dy-
namin-clathrin pathways (Figures S3C and S3F). These data
together suggest that opto-MOR may indeed recycle and use
clathrin-dynamin endocytosis, which has been documented in
opioid receptors (Gupta et al., 2014) and other GPCR systems
(Irannejad et al., 2013; Tsvetanova and von Zastrow, 2014),
and that opto-MOR may have some utility in dissecting these
diverse signaling dynamics.
Opto-MOR Expresses and Is a Functional Receptor in
DRG Neurons
To test whether opto-MOR is expressed and functions outside
the context of an artificial heterologous system, we generated
a Cre-dependent adeno-associated viral construct (Figure 3A),
whereby we inserted opto-MOR into a double inverted open
reading frame flanked by LoxP and Lox2227 sites (Zhang
et al., 2010). Utilizing this virus (AAV5-EF1a-DIO-opto-MOR-
YFP), we infected cultured dorsal root ganglia (DRG) neurons
from Advillin-Cre+ mice (da Silva et al., 2011; Zhou et al.,
2010). We did not detect any signal in uninfected control neurons
(Figure 3B). In Advillin-IRES-Cre+opto-MOR DRG neurons, we
observed opto-MOR expression in as little as 2 days post-trans-
duction (green, Figure 3C), suggesting rapid Cre-mediated exci-
sion in DRG. Strong opto-MOR expression was seen after 5 days
(Figure 3D), which partially co-localized with synapsin (Fig-
ure 3D), demonstrating that opto-MOR is trafficked efficiently
along neuronal processes and to presynaptic terminals. We
also show that following photostimulation of opto-MOR-ex-
pressing DRGs, there is an increase in pERK compared to un-
treated controls (Figures 3E and 3H). Following photostimulation
(1 min, 1 mW), we observed an increase in pERK levels 5 min
following an initial light stimulation that returns to basal levels
within 30 min (Figures 3F–3H). We also report evidence for pho-
tostimulated receptor internalization in these DRG cultures
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Figure 3. Opto-MOR Expression and Function in DRG Neurons
(A) Opto-MOR packaged into an AAV5-DIO-EF1a-YFP viral construct. Cre
expression is driven from the sensory neuron-specific Advillin promoter
following insertion after the initial start codon, resulting in Cre-mediated
recombination and inversion of the opto-MOR construct into the appropriate
50-30 orientation.
(B) Uninfected DRGs colabeled with the nuclear stain DAPI (blue) and
synapsin (red).
(C) Opto-MOR expression (green) in DRGs 2 days in vitro (DIV). Large arrow-
heads point to the soma of infected neurons.
(D) Opto-MOR expression (green) in DRGs 5 DIV. Small arrowheads highlight
opto-MOR expression in synaptic terminals colabeled with synapsin (red).
Scale bars for (B)–(D), 30 mm.
(E) Unstimulated opto-MOR expressed in DRGs after 5 DIV labeled with pERK
(red and inset).
(F) Opto-MOR expressing DRGs (5 DIV) 5 min following photostimulation and
labeled for pERK (red and inset). Open arrows denote internalized punctate
receptors.
(G) Higher magnification of opto-MOR expressing DRGs (5 DIV) 5min following
photostimulation and labeled for pERK (red and inset). Open arrows denote
internalized punctate receptors.
(H) pERK intensity normalized to opto-MOR-YFP intensity at varying times
following photostimulation (n = 3–32 DRG neurons per time point; ***p < 0.001
via one way ANOVA followed by Dunnett’s multiple comparison test to 0 min.
Scale bars for panels (E)–(G), 20 mm. Data are represented as mean ± SEM.(Figures 3F–3H), suggesting that the receptor can be dynami-
cally regulated in physiologically relevant systems. These data
closely mimic the kinetics of ERK activation seen in HEK293 cells
expressing opto-MOR (Figures 1J and 1K) and further support
the utility of using opto-MOR to dissect signaling in neuronal
preparations.
Opto-MOR Couples to Gbg-Mediated GIRK Currents in
PAG GABAergic Neurons
In order to assess whether opto-MOR couples to similar intracel-
lular signaling pathways following endogenous MOPR activation
in neurons, we focused on the periaqueductal gray (PAG),
which contains a high proportion of MOPR+ neurons (Vaughan
et al., 2003). We injected AAV5-EF1a-DIO-opto-MOR-YFP into
vGAT-IRES-Cre+ mice (Vong et al., 2011) within the PAG
(AP: 5.0 mm, ML: ± 0.5 mm, DV: 2.8 mm) and targeted
YFP+ GABAergic neurons for whole-cell recordings from acute
brain slices 2–3 weeks after injection. Photostimulation with
470 nm LED light (10 mW/mm2) evoked rapid outward currents
together with a simultaneous decrease in input resistance that
was reversed by bath application of barium (1 mM), a blocker
of GIRK currents (Figures 4A and 4B), suggesting that opto-
MOR activation leads to downstream activation of GIRK chan-
nels, which is consistent with the activation of endogenous
MOPR receptors in these neurons (Vaughan et al., 2003). A par-
allel set of experiments was performed onMOPR positive cells in
the PAG. Bath application of DAMGO (1 mM) showed similar out-
ward currents and decreased input resistance that were also
barium sensitive (Figures 4C and 4D). Voltage ramps performed
pre- and post-stimulation demonstrated current-voltage curves
consistent with the properties of GIRK channels, which were in-
hibited by barium (Figures 4G and 4H). Peak changes in holding
current and input resistance for opto-MOR (LED) and MOPR
(DAMGO) were not statistically different following stimulation,
or in the presence of barium (Figures 4E and 4F), suggestingNeuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc. 927
DAMGO barium
0 5 10 15 20 25
0
1
2
3
4
barium washout
(norm to pre-light)
time (min)
+ 470 nm LED + bariumopto-MOR positive
MOPR positive + 1 μM DAMGO + barium
-120 -100 -80 -60 -40 -20
-50
-25
0
25
50
75
100
opto-MOR GIRK current
opto-MOR
LED
barium
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
-2 0 2 4 6 8 10
time (min)
0
5
10
15
20
25
0
500
1000
1500
2000
2500
3000
0.0
0.5
1.0
1.5
2.0
2.5
3.0
A B C D
E F G H
I
J
K
L
pre-light
pre-light
0.0
0.5
1.0
1.5
2.0
2.5
bariumbarium
bariumbarium
LED
LED
LED
LED
0
10
20
30
40
DAMGO barium
0
500
1000
1500
2000
2500 DAMGO barium
200 ms
20 mV
0.0
0.5
1.0
1.5
2.0
2.5
DAMGO barium
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
-120 -100 -80 -60 -40 -20
-50
0
50
100
150
MOPR GIRK current
baseline
DAMGO
barium
0
5
10
15
20
25 -1500
-1000
-500
0
-20
-15
-10
-5
0 0
500
1000
1500
2000
Post-stimulation
LED DAMGO
1 mM barium
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
-2 0 2 4 6 8 10
time (min)
ho
ld
in
g 
cu
re
nt
 (p
A
)
ho
ld
in
g 
cu
re
nt
 (n
or
m
)
in
pu
t r
es
is
ta
nc
e 
(M
Ω
)
in
pu
t r
es
is
ta
nc
e 
(n
or
m
)
ho
ld
in
g 
cu
re
nt
 (p
A
)
in
pu
t r
es
is
ta
nc
e 
(M
Ω
)
ho
ld
in
g 
cu
re
nt
 (n
or
m
)
in
pu
t r
es
is
ta
nc
e 
(n
or
m
)
LED DAMGO LED DAMGO LED DAMGO w
ho
le
-c
el
l c
ur
re
nt
 (p
A
)
membrane potential (mV) membrane potential (mV)
w
ho
le
-c
el
l c
ur
re
nt
 (p
A
)
Δ 
ho
ld
in
g 
cu
rr
en
t (
pA
)
Δ 
in
pu
t r
es
is
ta
nc
e 
(M
Ω
)
Δ 
ho
ld
in
g 
cu
rr
en
t (
pA
)
Δ 
in
pu
t r
es
is
ta
nc
e 
(M
Ω
)
ho
ld
in
g 
cu
rr
en
t (
no
rm
)
0 5 10 15 20 25
time (min)
in
pu
t r
es
is
ta
nc
e 
(n
or
m
)
Figure 4. Photostimulation ofOpto-MOR andActivation of EndogenousMOPRsHave Similar Effects onNeuronal Physiology and Excitability
in GABAergic PAG Neurons
(A) Representative plots from an opto-MOR+ neuron in acute PAG slices illuminated with 470 nm LED light (10 mW/mm2) for 60 s. The top trace shows a rapid
outward current in response to illumination, while the bottom trace depicts the simultaneous drop in input resistance. Bath application of 1 mM barium (red
shading) both blocked the outward current and reversed the change in input resistance.
(B) Normalized summary plots showing the response to LED stimulation from additional opto-MOR+ neurons as described in (A) (n = 4).
(C) Example traces recorded from a MOPR+ neuron stimulated with 1 mM DAMGO (gray bars) showing similar outward currents (top) and decreased input
resistance (bottom) compared to opto-MOR+ neurons shown in (A) and (B).
(D) Normalized summary plots from additional MOPR+ neurons depicting the response to DAMGO as described in (C) (n = 4).
(E) Quantification of the peak changes in holding current and input resistance following LED (purple) or DAMGO (gray) stimulation (n = 4).
(F) Quantification of the peak changes in holding current and input resistance after application of 1 mM barium (n = 4).
(G and H) Representative current-voltage traces from a 250 ms voltage ramp from 20 to 120 mV, in an opto-MOR+ neuron (G) before (purple trace) and after
60 s LED stimulation (blue), or a MOPR+ neuron (H) before (black) or after stimulation with 1 mMDAMGO (gray). Both currents were reduced by the GIRK channel
blocker barium (1 mM, red).
(I and J) Left traces depict voltage traces from current-clamp recordings of an opto-MOR+ (purple traces) (I) or MOPR+ neuron (black) (J) in response to hyper-
polarizing current injections of 20 and 10 pA, and depolarizing current injections of 1- and 2-times rheobase. Middle traces show decreased input resistance
and excitability following LED (blue) and DAMGO (gray) in response to the same current injections before stimulation. The right traces demonstrate the increased
input resistance and neuronal excitability observed following GIRK channel block with 1 mM barium (red). Dashed lines indicate 60 mV membrane potential.
(K and L) Normalized summary plots of the persistent outward current (K) and decreased input resistance (L) in opto-MOR+ neurons following light stimulation and
subsequent barium washout (n = 3). These effects were observed >45 min after 60 s LED stimulation. The dashed lines indicate the average response before
illumination. Data are represented as mean ± SEM. See also Figure S4.
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Figure 5. Activation of Endogenous Mu-Opioid Receptors Occludes GIRK Channel Activation by Opto-MORs
(A) Example plots from an opto-MOR and MOPR+ GABAergic neuron in the PAG. An outward current and simultaneous decrease in input resistance were
observed following prolonged application of 1 mMDAMGO, which plateaued after5 min. Brief (5 s) LED illumination did not result in further changes to either of
these parameters.
(B) Example plots from a different neuron positive for both opto-MOR and MOPR in the presence of 1 mM DAMGO. The plateaued response to DAMGO is not
shown in this example. Prolonged LED illumination (blue, 60 s) did not alter the holding current or input resistance.
(C) Normalized summary graph showing the occluded responses to LED illumination following stimulation of endogenous MOPRs with DAMGO (n = 3).
(D) Quantification of the holding current and input resistance in the presence of DAMGO and following 5 s of LED stimulation (n = 3).
(E) Same quantification as in (D), but with 60 s illumination (n = 3).
(F) Representative GIRK channel ramp in the presence of DAMGO and following LED stimulation. Data are represented as mean ± SEM.that activation of both receptors is coupled to similar down-
stream effectors. We also found that activation of both opto-
MOR and MOPR substantially decreased neuronal excitability
in response to step current injections, which was also reversed
by application of barium (Figures 4I and 4J). We did, however,
notice a persistent outward current and significantly reduced
input resistance following washout of barium (Figures 4K and
4L), indicating that brief activation of opto-MOR can couple to
downstream effectors to suppress neuronal activity for an
extended period of time.
We next asked whether opto-MOR and MOPR activation en-
gages converging intracellular signaling cascades leading to
GIRK channel activation, or whether these two receptor popula-
tions signal through parallel subcellular pathways. To test this,
we recorded from MOPR+/YFP+ GABAergic neurons in the
PAG and applied saturating concentrations of DAMGO (1 mM).
We observed sustained outward currents coupled with a
decrease in input resistance (Figure 5A). After this response pla-
teaued, we stimulated neurons with either a brief LED light pulse(5 s, Figure 5A) or prolonged illumination (1 min, Figures 5B and
5C).We found that opto-MOR coupling toGIRK channel currents
and changes in input resistance were occluded by sustained
activation of endogenous mu-opioid receptors (Figures 5D–5F),
suggesting that activation of opto-MORs converge onto the
same pool of intracellular signaling cascades as endogenous
mu-opioid receptors. In addition, we injected AAV5-EF1a-DIO-
opto-MOR-YFP into the rostromedial tegmental nucleus
(RMTg) (AP: 3.9 mm, ML: 0.1 mm, DV: 4.5 mm) of a new
cohort of vGAT-IRES-Cre mice and targeted YFP+ interneurons
for whole-cell recordings. Photostimulation with 470 nm LED
light (10 mW/mm2) evoked outward currents together with a
decrease in the input resistance (Figures S4A andS4B), suggest-
ing opto-MOR activation is coupled to GIRK channels, which is
consistent with the endogenous MOPR function in these neu-
rons (Matsui and Williams, 2011; Matsui et al., 2014). Voltage
ramps performed pre- and post-stimulation demonstrated cur-
rent-voltage curves consistent with the properties of GIRK
channels (Lu¨scher et al., 1997) (Figure S4C).Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc. 929
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Figure 6. Photostimulation of Opto-MOR Causes MOR-like Behavioral Profiles In Vivo
(A and B) Mice with AAV5-DIO-opto-MOR-YFP injected into the RMTg (yellow) (A) with a fiber optic implanted into the VTA (red) and the ventral pallidum
(yellow) (B).
(C) Viral expression in VTA and RMTg.
(D) Viral expression in fibers (open arrows) projecting into the VTA (identified by tyrosine hydroxylase staining in red) as well as GABAergic interneurons of the VTA
(closed arrows).
(E) Viral expression in VP.
(F) Viral expression in VP GABA neurons (closed arrows).
(G and H) Mice expressing opto-MOR in the RMTg-VTA (n = 8) display significantly increased real-time preference behavior compared to controls (Cre-
littermates, n = 7) as shown by representative position heatmaps (G) and the mean preference for the stimulation-paired chamber (H).
(I and J) Mice injected into the VP (n = 16) display the converse aversion behavior in the place preference assay compared to controls (Cre littermate controls,
n = 5) spending less time in the light-stimulated chamber also shown by position heatmaps (I) and mean place preference results (J). *p < 0.05 via unpaired t test.
Data are represented as mean ± SEM. See also Figure S5.Taken together, these results from two different brain regions
suggest that opto-MOR couples to canonical MOPR G protein
signaling pathways, yet retains rapid photo-engagement of
opioid signal transduction pathways, making it an ideal tool for
spatiotemporal approaches to study MOPR signaling in real
time in vivo.
In Vivo Photostimulation of Opto-MOR in Selected
GABAergic Neurons Mediates Preference or Aversion
To demonstrate the utility of opto-MOR for studying opioid neu-
ral circuits in behavior, we locally infused AAV5-EF1a-DIO-opto-
MOR-YFP into the brains of two naive groups of vGAT-IRES-Cre
mice, one group in the RMTg (Figure 6A) and one group in the
ventral pallidum (VP) (Figure 6B), and waited at least 3 weeks
for optimal viral expression at the soma (Figures 6C–6F). Fiber930 Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc.optic implants (Sparta et al., 2012) were chronically implanted
above the VTA and the VP, respectively. Mice were placed into
black opaque boxes and allowed to explore both chambers
freely to evaluate preference or aversion behavior using the
real-time place preference assay. During testing, mice received
constant 10 mW 473 nm blue laser light upon entry into the ‘‘light
stimulation’’ side (Figures 6G and 6I). Preference and aversion
were calculated as the difference in time spent in the light-stim-
ulated box compared to the box with no stimulation, with prefer-
ence defined as more time spent in the photostimulated box and
aversion defined as less time in the photostimulation chamber.
vGAT-IRES-Cre+opto-MOR:RMTg mice displayed a significantly
greater preference for the stimulation than their Cre()-injected
opto-MOR littermate controls (Figures 6G and 6H, t13 = 2.231,
p < 0.05; Figures S5A and S5B). In addition, based on our data
demonstrating a power response relationship with opto-MOR in
activating cAMP and pERK (Figures 1H and S2I), we posited that
different light powers might produce different behavioral pheno-
types. As such, we focused on real-time place preference in
vGAT-IRES-Cre+opto-MOR:RMTg mice. We found that animals
receiving no light stimulation in the VTA show no preference for
either chamber (Figure S5I). However, when we increase the
power to 1 mW, animals begin to show a place preference and
spend more time in the conditioned chamber than those
receiving no light stimulation, but less time than those receiving
10 mW photostimulation (Figure S5I), thus demonstrating that
opto-MOR signaling can be more finely manipulated in vivo.
In contrast, mice injected with opto-MOR into the VP (vGAT-
IRES-Cre+opto-MOR:VP) displayed significant place aversion to
photostimulation, as compared to Cre() littermate controls (Fig-
ures 6I and 6J; t19 = 2.174, p < 0.05; Figures S5E and S5F).
Importantly, there were no differences in locomotor activity
throughout the session for either group (Figures S5C and S5G),
and light stimulation did not induce acute changes in locomotion
in the stimulation chamber (Figures S5D and S5H). Finally, as a
positive control, and to compare the efficacy of our opto-MOR
experiments for a more traditional optogenetic strategy, we
tested a new cohort of mice in which we inhibited GABAergic
neurons in the VTA using halorhodopsin (eNpH3.0) in the real-
time preference assay (Figures S5J–S5L) as previously reported
(Jennings et al., 2013). These data were strikingly similar to
inhibiting RMTg GABAergic neuronal population with opto-
MOR (Figure S5A), suggesting that inhibition of these popula-
tions has comparable behavioral phenotypes with alternative
optogenetic tools. Taken together, these behavioral results indi-
cate that opto-MOR functions to engage signaling and neuronal
inhibition with the ability to elicit robust real-time behavioral
responses.
DISCUSSION
Here we describe the development of a new opto-XR receptor
based on the mu-opioid receptor. We show that this opto-
MOR behaves functionally like its wild-type MOPR counterpart
in engaging canonical opioid G protein signaling pathways and
receptor internalization. Furthermore, we found that selective
expression of opto-MOR in GABAergic neurons within two
distinct brain regions promotes diverse behavioral responses
consistent with those previously observed with local MOPR
agonist infusion. This opto-MOR receptor could potentially
also be used alongside chemogenetic approaches, in peripheral
studies to assess nociceptive circuits, or as a robust way to
inhibit neuronal activity without the limits of the currently used
Cl and H+ pump approaches that include halorhodopsin or
archaerhodopsin (Berndt et al., 2014; Raimondo et al., 2012;
Wietek et al., 2014).
Opto-MOR Mimics Mu-Opioid Receptor Signaling
In Vitro
A few other opto-XR receptors have been reported (Airan et al.,
2009; Barish et al., 2013; Kim et al., 2005), including an opto-b2
adrenergic receptor as well as the recently described 5HT1A-like
opsin-chimera using the C-terminal components of the wild-typereceptor (Masseck et al., 2014). However, few reports have
directly examined the intracellular signaling dynamics of opto-
XR signaling as they relate to their wild-type receptor counter-
part, nor have these receptors been utilized in native circuits
where their endogenous complementary receptor types are ex-
pressed. This report shows side-by-side that GPCR Class A
rhodopsin-like chimeras can be generated to mimic neuropep-
tide receptor function in vitro. We found that opto-MOR indeed
engages inhibition of cAMP, couples to GIRK outward currents
in neurons, and activates ERK rapidly following light pulse expo-
sure (within 2 min), and finally that opto-MOR internalizes rapidly
in response to photostimulation. Furthermore, we show the
opto-MOR receptors functionally desensitize (Figures 2A and
2B), in a manner similar to that of their wild-type MOPR counter-
parts, suggesting that these receptors couple to native down-
regulation signaling pathways including G protein-coupled
receptor kinases (GRKs) and arrestins. In addition, our data
suggest that similar to other previously reported GPCRs, these
receptors may potentially signal at both membrane and intracel-
lular domains (Irannejad et al., 2013). The possibility therefore ex-
ists that opto-MOR may be capable of optical activation while
localized intracellularly, not only highlighting an important
caveat, but also illustrating the potential utility of this chimera
to elucidate components of intracellular signaling cascades.
However, future studies to examine opto-MOR regulation of
signaling dynamics in native neurons are required, and mutation
of the opto-MOR receptor at C-terminal sites previously associ-
ated with receptor regulation could potentially provide advanta-
geous optogenetic tools in dissecting MOPR-related signaling
and tolerance in vivo.
In Vivo Utility of Opto-MOR for Behavioral Optogenetic
Studies
We primarily generated this unique tool to facilitate mimicry of
opioid signaling in vivo for use in optogenetic studies. The ability
to time-lock activation of mu-opioid-like signaling in an awake-
behaving animal provides an alternate approach for mapping
the role of opioid receptor signaling in discrete neural circuits
and cell populations in real time. In order to demonstrate the util-
ity of this approach in vivo, we chose two brain regions widely
known to express high levels of endogenous MOPR that have
previously been linked to mu-opioid-dependent reward and
aversion. In a first series of experiments, we examined the
effects of opto-MOR expression in VTA/RMTg GABAergic neu-
rons using real-time place testing. Recent work had demon-
strated that mu-opioid receptors are expressed on both local
VTA interneurons as well as a large proportion of nearby RMTg
GABAergic cells. It is hypothesized that these receptors likely
act to disinhibit dopaminergic activity resulting in MOPR-medi-
ated reward behavior. We demonstrate here that photostimula-
tion of opto-MORVGATcre+ receptors in RMTg neurons produces
real-time place preference and reward seeking behavior. This
result is consistent with reports using mu-opioid agonists
into this region (Jalabert et al., 2011; Jhou et al., 2012; Matsui
et al., 2014). In addition, prior reports have demonstrated
that optogenetic activation or inhibition of VTA and RMTg
GABAergic neurons drives real-time place preference or aver-
sion behavior (Tan et al., 2012; van Zessen et al., 2012), furtherNeuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc. 931
suggesting that these VTA neuronal populations are poised to
regulate dopaminergic output and behavior.
The ventral pallidum (VP) region is well known to express mu-
opioid receptors, and regional activation has been reported to
lead to both reward and aversive behavioral responses (Hjelm-
stad et al., 2013). We therefore expressed opto-MOR in VP
GABAergic neurons and selectively targeted coordinates corre-
sponding to the previously reported opioid ‘‘hedonic cold spot’’
(Smith and Berridge, 2005; Smith et al., 2009) in order to deter-
mine if activation of opto-MOR signaling in this region could elicit
real-time aversion. Consistent with prior reports showing that
MOPR agonism in this anterior central region decreases reward
seeking (Smith et al., 2009), we observed that opto-MOR activa-
tion within these neurons produced avoidance of the photosti-
mulation chamber. These two behavioral assays demonstrate
that opto-MOR can elicit robust real-time opioid-like behavioral
responses in vivo and highlight their utility for future studies
examining circuit and cell-type functions of this pathway.
In addition, these in vitro and in vivo findings coupled with our
evidence of coupling to GIRK signaling highlight the utility of
opto-MOR for more generalizable optogenetic inhibition studies,
such as those that are routinely conducted using halorhodopsin
or archaerhodopsin. Opto-MORcouples to native signaling path-
ways to regulate neuronal activity via GIRKs and might be
preferred since it does not come with the potential caveats that
the photosensitive chloride pumps (eNpHR3.0) bring with them,
including alterations in the reversal potential of theGABAA recep-
tor, that lead to changes in synaptically evoked spiking activity in
the period after photoactivation (Raimondo et al., 2012). Future
work utilizing opto-MOR in other neuronal cell types and circuits
is warranted, however, for determining its utility as a broadly
generalizable optogenetic inhibition approach.
Limitations and Future Directions
Although we have developed a photosensitive mu-opioid-like re-
ceptor for the interrogation of opioid neural circuits in vitro and
in vivo, there are some potential limitations of this approach
that are worth noting. We chose to use vertebrate rhodopsin
as a backbone for generation of opto-MOR because it has pre-
viously been shown to couple to Gi/o-related signaling (Li
et al., 2005) and thus made for an ideal chimeric approach. How-
ever, this choice of rhodopsin has limitations since the receptor
is very photosensitive, as indicated in our in vitro studies and
in vivo behavior. This is an important consideration when using
the tool in vitro for slice physiology and circuit analysis, as well
as in vivo, whenwanting to elicit discrete activation in a particular
anatomic subregion. To work around these caveats, we were
careful to use the tool under red light conditions in vitro, and
while in vivo we kept the fiber implants capped. To resolve
this, future variants might be warranted with mutations that
render opto-MOR less photosensitive and/or use other short-
wavelength opsins as part of the chimeric design.
It is also important to note that the receptor is only partially a
mu-opioid receptor and thus might display a different protein-in-
teractome than the wild-type MOPR. Indeed, we show that the
receptor utilizes a pool of intracellular signaling similar to that
of MOPR (Figures 1 and 2) and traffics to synapses (Figure 3);
however, recent work has suggested a complex regulatory pro-932 Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc.teome of MOPR interactions (Al-Hasani and Bruchas, 2011), and
thus we are careful to interpret our data in light of known trans-
membrane and extracellular loop residues that are important
for MOPR function in neurons.
Future studies using the opto-MOR in side-by-side experi-
ments with other exciting recent developments (Banghart and
Sabatini, 2012) in optical control of neuropeptide function should
provide researchers with a means to better dissect the role of
opioid neuropeptide signaling in complex neural circuits and in
freely moving mice (Kim et al., 2013). Understanding the relative
dynamics of neuropeptide release and receptor signaling is a
key question in neuroscience, and opto-XRs that mimic endog-
enous signaling pathways hold promise in delineating some of
these mechanisms. Furthermore, there is a growing need to
better understand the molecular-cellular mechanisms of opioid
tolerance in pain, and thus the optodynamic properties of this
approach may have utility in this arena. The use of this tool will
provide an additional layer of spatiotemporal specificity when
used with traditional pharmacology, physiology, and behavioral
approaches.
Conclusions
In summary, here we provide and characterize a novel tool for
neuroscience that allows for spatiotemporal control of opioid re-
ceptor signaling in vitro and in vivo. Opto-MORs functionally
couple to canonical intracellular signaling pathways and have
utility in dissecting opioid contributions to behavioral effect.
The combination of opto-XR approaches with chemogenetic
and traditional optogenetic channel approaches expands our
toolbox for understanding neuropeptide signaling within neural
circuits, within real-time, freely moving animals. Furthermore,
advances in receptor chimeras such as opto-MOR will facilitate
the generation of additional related approaches for other GPCR
classes.
EXPERIMENTAL PROCEDURES
Construct Design and Cloning
Using the constraint-based multiple alignment tool (COBALT, NCBI; http://
www.st-va.ncbi.nlm.nih.gov/tools/cobalt/re_cobalt.cgi), rat rhodopsin 4
(RO4) sequences were aligned against rat MOR. RO4 extracellular domains,
including the retinal binding site, and transmembrane domains were identified
and conserved. HindIII/EcoRI sites were added to the N terminus while Xhol/
BamHI sites were added to the C terminus of the chimeric sequence. The
stop codons were replaced with leucine residues, and silent mutations were
added to remove an endogenous Xhol restriction digest site 990 bp into the
gene. The construct was synthesized by IDT in a non-expressing pSMART
vector (Lucigen) then cloned without stop codons into pcDNA3-YFP (Invitro-
gen) containing ampicillin resistance cassettes and CMV promoter regions
for expression in mammalian cells. Restriction enzyme digest sites EcoRI
and XhoI were used to excise the opto-receptor construct from the pSMART
vector and purified by gel extraction. pcDNA3-YFP was also digested with
EcoRI, and Xhol and T4 Ligase were used to ligate opto-MOR into the vector.
E. coli was transformed with pcDNA3-opto-MOR-YFP plasmids, plated on
ampicillin-containing plates. GeneWiz verified chimeric sequence integrity.
Rat MOR-GFP was kindly donated from the lab of Dr. Charles Chavkin at Uni-
versity of Washington, Department of Pharmacology (Celver et al., 2004).
Real-Time Measurement of cAMP Dynamics
Stable HEK cell lines containing opto-MOR and MOR were transfected
with the pGloSensor-22F cAMP plasmid (Promega E2301) using JetPrime
(Polyplus) transfection reagent per manufacturer’s instructions. Stable co-
transfected cells were maintained under both G418 (400 mg/ml) and hygrom-
ycin (200 mg/ml) selective pressure. The day before an experiment, cells
were plated on 96-well tissue culture-treated plates (Costar), 60K–100K
cells/well, and allowed to recover overnight at 37C, 5% CO2. The next day,
media was replaced with 2% GloSensor reagent (Promega) suspended in
CO2-independent growth medium (GIBCO) and incubated for 2 hr at 37
C.
For real-time cAMP, a baseline was first obtained with no treatment by
recording relative luminescent units (RLUs) every 6 s for 1 min using a
SynergyMx microplate reader (BioTek). 1 mM forskolin (dashed line in each
figure) was applied to each well, and RLUs were recorded for 3 min. Cells
were then treated with either a 20 s, 1 mW, blue LED pulse or 1 mM DAMGO
(Tocris) and RLUs recorded for an additional 10 min. For data expressed
as cAMP (fold baseline), RLUs for 1 min of baseline were averaged and all
subsequent RLUs were then divided by this average. For data expressed as
cAMP (percent max), raw RLUs were entered into GraphPad Prism (v5.0d,
GraphPad Software), and the normalization function was used to assign the
lowest RLU a value of 0% and the highest RLU a value of 100%. Time
constants were calculated in GraphPad Prism using one-phase association
(Y = Y0 + (Plateau-Y0)*(1-exp(K*x))) nonlinear regression analyses yielding
a time constant value (ton). For cAMP (percent control) data, area under the
curve for each treatment group was normalized to its corresponding experi-
mental control. Each data point is a minimum of three wells per experimental
replicate.
Immunoblotting
Immunoblotting for MAPK activation was performed as previously described
(Bruchas et al., 2011). Opto-MOR and MOPR expressing cells were grown
to 100% confluency in 24-well plates. Cells were serum starved in plain
DMEM for at least 4 hr before drug or LED treatment using Plexon LED Driver
LD-1 (465 nm). Cells were harvested in 500 ml of lysis buffer containing (in
mM) 50 Tris-HCl, 300 NaCl, 1 EDTA, 1 Na3VO4, 1 NaF, 10% glycerol, 1%
Nonidet P-40, and 1:100 of phosphatase and protease inhibitor mixture set
(Calbiochem, EMD Millipore). Lysates were sonicated for 10 s and spun
down for 20 min (14,000 3 g, 4C). 25 mg protein was run in each well,
and blots were transferred to nitrocellulose (Whatman), blocked with 5%
FBS albumen for 1 hr, then incubated with 1:1,000 goat anti-rabbit
pERK1/2 (phospho Thr-202/Tyr-204; Cell Signaling) and 1:20,000 goat anti-
mouse b-actin (Abcam) antibodies at 4C overnight. Membranes were
washed 4 times for 10 min each in Tris-buffered saline and 0.1% Tween-
20 (TBST) and incubated with 1:10,000 IRDyeTM 800- and 700-conjugated
affinity-purified anti-rabbit or anti-mouse IgG in a 1:1 mixture of 5% milk/
TBS and Li-Cor blocking buffer (Li-Cor Biosciences) for 1 hr at room temper-
ature. Membranes were washed 4 times for 10 min each with TBST, then 2
times with TBS to remove Tween. Blots were visualized, background sub-
tracted, and quantified with Odyssey Infrared Imager (Li-Cor Biosciences).
pERK bands were normalized to b-actin from each sample and calculated
as fold increase from baseline or as percent of maximal ERK phosphorylation
as appropriate.
Receptor Internalization and Confocal Microscopy
Opto-MOR-YFP and MOPR-GFP-expressing cells were plated to approxi-
mately 50% confluence on poly-D-lysine-coated coverslips (Becton Dickin-
son). Following LED (1 W/cm2, 1 min) or DAMGO (1 mM) treatment, cells
were washed 3 times with PBS and then fixed with 4% paraformaldehyde.
Coverslips were then mounted with Vectashield Hard Set mounting medium
with DAPI (Vector Laboratories) and imaged on a Leica TCS SPE confocal
microscope (Leica), and Application Suite Advanced Fluorescence (LAS AF)
software calculated receptor internalization (inside fluorescence/total fluores-
cence 3 100).
Animal Subjects
Group-housed adult (25–35 g) male vGAT-IRES-Cre mice (Vong et al.,
2011) and Cre() littermate controls were used for all in vivo experiments.
For eNpH3.0 VTA GABA experiments (see Supplemental Materials),
GAD2-Cre mice were used. All mice were maintained on a 12 hr light:12 hr
dark cycle and given ad libitum access to food and water. The WashingtonUniversity in St. Louis Animal Studies IACUC approved all experimental
methods.
Viral Injections and Surgical Procedures for Fiber Optic Placement
All surgeries were performed under isoflurane anesthesia (Piramal Healthcare,
Maharashtra, India). For slice physiology experiments, adult mice were
injected bilaterally with AAV5-EF1a-DIO-opto-MOR-eYFP. For behavior
experiments, adult male mice were injected unilaterally with 500 nl of AAV5-
EF1a-DIO-opto-MOR-eYFP virus (WUSTL Hope Center Viral Core, St. Louis,
MO) into the RMTg (AP: 3.9 mm, ML: 0.1 mm, DV: 4.5 mm) or the VP
(AP: 0.7 mm, ML: 1 mm, DV: 5.25 mm). Fiber optic ferrules were chronically
implanted above the VTA (AP: 3.4 mm, ML: 0.5 mm, DV: 4.0 mm) or the
VP (AP: 0.7 mm, ML: 1 mm, DV: 4.8 mm), respectively, and dental cement
(Lang Dental, Wheeling, IL) was applied to hold the ferrules in place (Sparta
et al., 2012). Mice were allowed to recover for at least 3 weeks following infu-
sion of virus and fiber placement prior to further behavioral testing.
Slice Physiology
Acute brain slices were prepared using a protective cutting and recovery
method (Ting et al., 2014). Anesthetized mice were transcardially perfused
with NMDG-substituted aCSF containing (in mM) 93 NMDG, 2.5 KCl, 1.25
NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 5 ascorbic acid, 2 thiourea,
3 Na-pyruvate, 12 N-acetyl-L-cysteine, 10 MgSO4, 0.5 CaCl2 (pH = 7.3).
200 mm thick coronal sections of the PAG were cut using a Vibratome
VT1000s (Leica) and transferred to an oxygenated recovery chamber contain-
ing NMDGaCSF for 5–10min at 32C –34Cbefore being transferred to a hold-
ing chamber filled with modified aCSF containing (in mM) 92 NaCl, 2.5 KCl, 1.2
NaH2PO4, 30 NaHCO3, 20 HEPES, 25 glucose, 2 CaCl2, 2 MgCl2 (pH adjusted
to 7.3 with NaOH), and Osm 300-315 and incubated in the dark at room
temperature for >1 hr before recording. 225 mm thick sagittal sections were
prepared for experiments in RMTg. Additional details can be found in the
Supplemental Experimental Procedures.
Behavior
Real-Time Place Preference and Aversion, rtPP/A
Mice were placed into a custom-made black acrylic two-chambered box
(52.5 3 25.5 3 25.5 cm) and allowed to explore each of two chambers for
60 min. Using Noldus Ethovision hardware controller connected to a master
9 functional generator, light stimulation (473 nm, 10 mW) was delivered
through fiber optic implants during the duration of their time spent in the
‘‘conditioned’’ side of the chamber, and mice received no stimulation on the
‘‘unconditioned’’ side. The experimental animals were counterbalanced for
both group and conditioning side. Preference and aversion scores in each
experiment were determined by comparing the amount of time spent in the
conditioned versus unconditioned sides during the real-time testing phase.
Preference (RMTg) and aversion (VP) were calculated by comparing time spent
in the light stimulation box with time spent in the no stimulation box during the
final 30 min of the test session. All behavioral data (locomotion, velocity,
entries) were analyzed using Noldus Ethovision (v9.5) with a ZR900 Canon
camera.
Immunohistochemistry
As previously described (Kim et al., 2013), after the conclusion of behavioral
testing, mice were anesthetized with sodium pentobarbital and transcardially
perfused with ice cold PBS, followed by 4% phosphate-buffered paraformal-
dehyde. Brains were removed, post-fixed overnight in paraformaldehyde, and
saturated in 30% phosphate-buffered sucrose. 50 mm sections were cut,
washed in 0.3% Triton X-100/5% normal goat serum in 0.1 M PBS, stained
with fluorescent Nissl stain (1:400 Neurotrace, Invitrogen) for 1 hr, and
mounted onto glass slides with Vectashield (Vector Laboratories). VTA sec-
tions were stained with rabbit anti-tyrosine hydroxylase (1:1,000, Millipore)
overnight at 4C and AlexaFluor 633 goat anti-rabbit for 2 hr at room temper-
ature (1:1,000, Molecular Probes) prior to the Nissl step. Opto-MOR expres-
sion was verified using fluorescence (Olympus) and confocal microscopy
(Leica Microsystems). Images were produced with Leica Application Suite
Advanced Fluorescence software. Animals that did not show targeted expres-
sion were excluded.Neuron 86, 923–935, May 20, 2015 ª2015 Elsevier Inc. 933
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